Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levilimab in Severe COVID-19
NCT04397562Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Levilimab Group with Placebo Group (2 arms). Primary endpoint: Proportion of patients with sustained clinical recovery at Day 14. Started Apr 2020; status: completed.
02
Drugs
levilimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04397562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397562.